ASX and Frankfurt Stock Exchange-listed PharmAust has unveiled encouraging initial results from the continuing phase IIb clinical trial of its anti-cancer drug, Monepantel on pet dogs suffering from B-cell lymphoma. The Perth-based company says the first five dogs who have undergone treatment with Monepantel across five participating test sites show “minimal side effects”.
30/03/2021 - 14:05
Positive signs for PharmAust K9 anti-cancer drug trial
By Matt Birney
30/03/2021 - 14:05
Related Data & Insights
-
-
Rank Company Revenue th PharmAust $842k 201 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Data & Insights
Mentioned Organisations
Mentioned People
Related Articles
21 Jun 2024
PharmAust taps investors for $10m
31 May 2024
Shares rise following Thurn return
17 May 2024
Board Moves May 17, 2024
17 May 2024
PharmAust receives FDA approval
24 Apr 2024
Board Moves, April 24 2024
23 Apr 2024
PharmAust CEO resigns
Subscribe today for award-winning, unbiased and trusted journalism
Subscription OptionsX